Search Results
38 Results Found for “stroke recurrence”
Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Presented at EHRA 2026 by Dr David Birnie, the OCEAN trial reveals low, brief atrial fibrillation recurrence rates after successful ablation - findings that may support selective anticoagulation discontinuation while reinforcing the need for ongoing follow-up.
New perspectives from ESC 2025 point to cryoablation as a streamlined and safer option for managing atrial fibrillation in heart failure, offering the potential for earlier treatment and broader access in busy healthcare systems.
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
The Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation (BEAT-AF) treatment project is an initiative funded by the European Commission from the European Union's Horizon 2020 research and innovation programme, and managed under the European Health and Digital Executive Agency (grant number 945125).1,2 The ...
Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation ...
Catheter ablation (CA) is an invasive adjunctive therapeutic option for atrial and ventricular arrhythmias, in uncontrolled cases, following optimal medical therapy.1,2 The validation of 3D mapping and its implementation into clinical usage has been a remarkable achievement in the field ...
The prevalence of aortic stenosis (AS) has grown over the last few decades, as life expectancy has increased. AS is the most common valvular disease in the developed world and is found in up to 9.8% of individuals aged ≥75.1–3 The wide ...
A significant proportion of patients with atrial fibrillation (AF) who have a high stroke risk are currently being treated with oral anticoagulation (OAC), including direct oral anticoagulants (DOACs) and vitamin K inhibitors (VKAs).1 It is well known that the increased ...
Heart failure (HF) and atrial fibrillation (AF) are inexorably linked. They frequently coexist and share common risk factors, including ageing, hypertension, diabetes, obesity, sleep apnoea and coronary disease.1–4 Over half of patients with HF develop AF at some point,5 and ...
In this article, we review prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis (CAT), discuss specific factors that influence anticoagulant choice, and explore ongoing trials that may impact treatment in the future. Older data estimated ...
Atrial fibrillation (AF) is the most common type of treated cardiac arrhythmia. The prevalence of the condition increases with age, and it presents with a wide spectrum of symptoms and severity. As the population ages, particularly in developed countries, the ...
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of morbidity and mortality; however, an optimal strategy for its management remains somewhat unclear, especially for patients with persistent AF.1 Electrical cardioversion (ECV) is widely used ...
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable ...
As clinicians and academics, we have at least three reasons for developing a simple stepwise algorithm for the management of atrial fibrillation (AF) with rapid ventricular response (RVR) in the emergency department (ED). First, AF is the most common rhythm ...
Cryptogenic stroke (CS) is a brain infarction that cannot be clearly attributed to cardioembolism, large-vessel atherosclerosis or small artery disease, despite extensive clinical evaluation.1 It represents approximately one-third of all ischaemic strokes worldwide.2 Stroke represents a major public health crisis, ...
Several smart, connected and direct-to-consumer wearable devices capable of detecting cardiac arrhythmias have proliferated in the marketplace in the last decade. Increasingly, these devices are being marketed as “medical grade” in addition to “wellness” devices.1 New iterations of smartwatch and ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
